The Evidence Based Rheumatology Podcast

The Evidence Based Rheumatology Podcast header image 1

E37: TRACE-RA Atorvastatin for Primary Prevention of CVD in RA

April 18th, 2019

This week I pair the recently published TRACE-RA trial assessing the efficacy of atorvastatin in primary prevention of cardiovascular disease. It offered a great opportunity to also go after the recent Nature publication "Scientists rise up against statistical significance," which has (inexplicably) gotten so much high praise.  

Subscribe to the podcast / my twitter feed and find the papers at!

E36: Baricitinib for SLE

April 4th, 2019

This week I discuss the phase 2 trial on baricitinib in SLE.  Though it's early times (and the total flop of rituxan in ME/CFS recently can attest to this), this was a large phase 2 and I'm hopeful it carries through to the ongoing phase 3 trials.  Follow me on twitter and find all the papers / links at my new landing page,!

E35: Tramadol Associated with All Cause Mortality

March 28th, 2019

#RheumJC week!  I hope you all tuned into the online journal club #RheumJC, but if you did not I put up a podcast about the paper we discussed. Yet another epidemiological misadventure into unmeasured confounding and in this case confounding by indication.  Take home... maybe consider not using Tramadol, as you already should have not been doing? 

Article I reference in the podcast:

All the papers!

Follow me @EBRheum. 

E34: Leggo my Eggo! Eggs, Cholesterol, CVD, Mortality

March 21st, 2019

In this week's episode I depart briefly from discussing papers in the rheumatology literature to dive headfirst into the recent controversy over eggs and cardiovascular disease. Our patients eat eggs too, so I figured it would still be applicable. Please join the conversation @EBRheum! Find all the papers here:

E33: FDG-PET for GCA

March 14th, 2019

This week I'll tackle an interesting topic in giant cell vasculitis - the utility of FDG PET. This was a good paper but one that I used to discuss important concepts, including negative predictive value and pretest probability.  Hope you enjoy!  Please give feedback @EBRheum! Find all the papers here:

E32: TaSER and ARCTIC: U/S to Guide Treatment in Inflammatory Arthritis

March 7th, 2019

Finally addressing this ultrasound business.  I decided to cover two somewhat similar trials, which seem to come to the same conclusions regarding U/S and treat to target strategies.  However, the question addressed was narrow and the role of ultrasound remains to be determined.  Get this paper (and all the others) here:

E31: SEAM and MIPA Trials: MTX vs. ETN for Psoriatic Arthritis

February 28th, 2019

This week we tackle two RCTs and try to figure out what to do with etanercept, methotrexate, and placebo (or the lack thereof).  Good opportunity for jumping into more PsA trials in the near future - lots of IL-somethings to talk about!  Remember to follow the podcast @EBRheum to give feedback and for updates! 

E30: The Quality of RCTs in the Rheum Literature

February 21st, 2019

We're back!  This week I discuss work I did for the rheumatology winter clinical symposium on the quality of RCTs in the rheumatologic literature.  Be sure to follow the twitter handle for a descriptive slide and to weigh in on the podcast! @ebrheum

E29: CIRT and CANTOS - Immunotherapy for Cardiovascular Disease

November 21st, 2018

Double episode this week and then I'll be taking the holidays off.  I decided to combine two trials of immunotherapy for secondary prevention of cardiovascular disease, the CANTOS trial (canakinumab vs. placebo) and the CIRT trial (methotrexate vs. placebo).  It was a good opportunity to debunk both therapies and take a few pot shots at observational trials, "bioplausibility," and surrogate endpoints. Both papers are available on my box account here.

E28: Nurse Run Treat to Target vs. Usual Care? in Gout

November 11th, 2018

Interesting trial this week pitting an elaborate nurse led group against suboptimal usual care.  Suboptimal usual care lost pretty badly, but what to make of this?  And does it support the rheumatologist side of the treat to target controversy?  Listen to find out and be sure to follow on @EBRheum if you have your own thoughts!